FUS Proteinopathy Neurons

📖 Wiki Page

cell1369 wordssynced 2026-04-02

FUS Proteinopathy Neurons

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">FUS Proteinopathy Neurons</th>
</tr>
<tr>
<td class="label">Mutation</td>
<td>Protein Change</td>
</tr>
<tr>
<td class="label">R521C</td>
<td>Arginine → Cysteine</td>
</tr>
<tr>
<td class="label">R521G</td>
<td>Arginine → Glycine</td>
</tr>
<tr>
<td class="label">R522G</td>
<td>Arginine → Glycine</td>
</tr>
<tr>
<td class="label">P525L</td>
<td>Proline → Leucine</td>
</tr>
<tr>
<td class="label">P525R</td>
<td>Proline → Arginine</td>
</tr>
<tr>
<td class="label">R487L</td>
<td>Arginine → Leucine</td>
</tr>
<tr>
<td class="label">R487Q</td>
<td>Arginine → Glutamine</td>
</tr>
<tr>
<td class="label">G507D</td>
<td>Glycine → Aspartic Acid</td>
</tr>
<tr>
<td class="label">H517Q</td>
<td>Histidine → Glutamine</td>
</tr>
</table>

Introduction

FUS (Fused in Sarcoma) proteinopathy represents a critical pathological hallmark in a subset of neurodegenerative diseases, particularly Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). FUS Proteinopathy Neurons are characterized by the accumulation of misfolded FUS protein in the cytoplasm, leading to disruption of normal cellular functions and ultimately neuronal death[@kwiatkowski2009][@vance2009].

This page provides comprehensive information about FUS-positive neurons, their molecular mechanisms, genetic contributors, and therapeutic strategies targeting this pathology.

...

FUS Proteinopathy Neurons

Introduction

This page provides comprehensive information about FUS-positive neurons, their molecular mechanisms, genetic contributors, and therapeutic strategies targeting this pathology.

Overview

Neurons exhibiting FUS proteinopathy feature cytoplasmic inclusions of mutated or mislocalized FUS protein. FUS mutations are responsible for approximately 5% of familial ALS cases and up to 10% of juvenile-onset ALS[@shang2016]. Unlike TDP-43 proteinopathy, which is the most common pathology in sporadic ALS, FUS pathology is associated with specific genetic subtypes and distinct clinical phenotypes.

The FUS protein is a member of the FET (FUS, EWSR1, TAF15) family of RNA-binding proteins, which are involved in multiple aspects of RNA metabolism including transcription, splicing, transport, and translation[@dormann2011].

FUS Biology

Normal Physiological Function

FUS (Fused in Sarcoma), also known as TLS (Translocated in Sarcoma), is a 526-amino acid nuclear protein with multiple functional domains:

N-terminal prion-like domain: Enables liquid-liquid phase separation and stress granule formation
RRM (RNA recognition motif): Binds RNA molecules
RGG (arginine-glycine-glycine) repeats: Involved in protein-protein interactions
Zinc finger domain: Mediates nucleic acid binding

In healthy neurons, FUS performs critical functions[@ito2022]:

RNA splicing regulation: FUS participates in the spliceosome assembly and regulates alternative splicing of numerous neuronal transcripts
Transcription regulation: Interacts with RNA polymerase II and transcriptional co-activators
DNA damage response: FUS is recruited to DNA damage sites and participates in repair pathways
Stress granule formation: During cellular stress, FUS localizes to stress granules, membrane-less organelles that temporarily store mRNAs
Axonal transport: Facilitates transport of mRNAs along axons for local protein synthesis

Pathological Changes in FUS Proteinopathy

The transition from normal FUS function to pathological aggregation involves several key steps[@liu2023]:

Nuclear-cytoplasmic mislocalization: Mutations or cellular stress cause FUS to accumulate in the cytoplasm instead of remaining nuclear

Nuclear clearance: FUS levels in the nucleus decrease dramatically

Stress granule sequestration: Abnormal FUS becomes trapped in stress granules, which persist rather than resolving

Aggregation: FUS forms stable, insoluble inclusions that resemble stress granules but are distinct

RNA processing disruption: Aberrant FUS disrupts normal RNA splicing and transport

Genetic Basis

Disease-Causing Mutations

Over 50 FUS mutations have been identified in ALS and FTD patients[@lenz2023]:

Inheritance Patterns

Autosomal dominant: Most FUS mutations exhibit dominant inheritance
De novo mutations: Many juvenile cases arise from spontaneous mutations in sperm or egg cells
Anticipation: Earlier onset in successive generations (controversial)

Affected Brain Regions

FUS proteinopathy preferentially affects specific neuronal populations[@neumann2009]:

Primary Affected Regions

Motor cortex: Upper motor neurons show FUS inclusions; critical for voluntary movement control
Spinal cord motor neurons: Lower motor neurons in the anterior horn are severely affected; leads to muscle weakness and atrophy
Premotor cortex: Involved in movement planning; contributes to pseudobulbar affect
Primary somatosensory cortex: Some involvement affects sensory processing

Secondary Affected Regions

Basal ganglia: Particularly the striatum; contributes to movement disorders
Hippocampus: CA1 and subiculum regions show FUS pathology in some cases
Frontal cortex: Particularly in FTD cases; affects executive function
Cerebellar granule cells: Less commonly affected
Substantia nigra: Dopaminergic neurons may show FUS pathology

Pathogenic Mechanisms

RNA Processing Defects

FUS proteinopathy disrupts multiple aspects of RNA metabolism[@ho2022]:

Alternative Splicing Aberrations

Intron retention increases in neuronal transcripts
Exon skipping events disrupt protein coding
Alternative exon usage alters protein isoforms
Key neuronal transcripts affected include:
MAPT (tau)
UNC13A
STMN2
Progranulin (GRN)

mRNA Transport Impairment

Reduced dendritic mRNA localization
Impaired local translation at synapses
Synaptic protein synthesis deficits
Contributing to synaptic dysfunction

Translation Dysregulation

Global translation reduced due to stress granule sequestration
Specific translation programs disrupted
Ribosome stalling on affected transcripts

Stress Granule Dysregulation

Stress granules are membrane-less organelles that form under cellular stress[@dao2021]:

Normal Stress Granule Function

Form rapidly in response to stress
Contain translationally stalled mRNAs and RNA-binding proteins
Resolve when stress subsides
Protect mRNAs during stress

Pathological Granule Dynamics in FUS Proteinopathy

Aberrant granule formation even at baseline stress levels
FUS inclusions persist indefinitely
Sequestration of essential translational machinery:
eIF3
PABPN1
TDP-43
Impaired stress response resolution
Formation of toxic intermediate species

Nucleocytoplasmic Transport Defects

FUS mutations disrupt nuclear-cytoplasmic transport[@japtok2022]:

Nuclear pore complex integrity compromised
Importin-α/β trafficking disrupted
Nuclear envelope breakdown in some cases
RNA export受阻 (impaired)
Nuclear accumulation of unspliced transcripts

DNA Damage Sensitivity

FUS plays a direct role in DNA repair[@wang2023]:

Impaired DNA Damage Response

Reduced recruitment to DNA damage sites
Defective homologous recombination
Increased sensitivity to genotoxic stress
Accumulation of DNA mutations

Genomic Instability

Chromosomal breaks increase
Translocation events more common
Mutator phenotype develops
Contributes to neurodegeneration

Mitochondrial Dysfunction

FUS pathology affects mitochondrial health[@tradewell2022]:

Reduced mitochondrial transport along axons
Impaired mitochondrial dynamics (fusion/fission)
Decreased ATP production
Increased reactive oxygen species (ROS)
Mitochondrial permeability transition pore opening

Clinical Correlations

ALS Phenotype

Rapid progression: FUS mutations often cause aggressive disease
Young onset: Average onset 40-50 years (younger than typical ALS)
Bulbar onset: More common than in sporadic ALS
Cognitive involvement: Some develop FTD features
Respiratory involvement: Early respiratory muscle weakness

FTD Phenotype

Behavioral variant FTD: Most common presentation
Language variant: Some develop primary progressive aphasia
Parkinsonism: May accompany cognitive changes
Motor neuron disease: Up to 15% develop ALS

Therapeutic Approaches

Antisense Oligonucleotide (ASO) Therapy

ASOs represent the most promising targeted approach[@bhattacharya2024]:

Mechanism: Single-stranded DNA oligonucleotides that bind complementary mRNA
FUS-targeted ASOs: Currently in preclinical development
Delivery: Intrathecal administration to reach CNS
Challenges:
Efficient delivery to neurons
Allele-specific targeting needed for dominant mutations
Timing of intervention

Small Molecule Approaches

Localization Modulators

Compounds promoting proper FUS nuclear localization
Targeting nuclear import machinery
In development phase

Stress Granule Modulators

Inhibiting abnormal stress granule formation
Promoting granule clearance
Examples:
ISRIB (integrated stress response blocker)
Mitochondrial division inhibitors

RNA Processing Modulators

Splicing modifier compounds
Restoring normal alternative splicing
Targeting specific mis-spliced events

Gene Therapy

CRISPR-based approaches: Gene editing to correct mutations
AAV delivery: Engineered vectors for neuronal transduction
Allele-specific editing: Targeting mutant allele only
Regulatory element manipulation: Modulating FUS expression

Neuroprotective Strategies

Anti-oxidants: Mitigating ROS damage
Anti-apoptotic compounds: Preventing cell death
Neurotrophic factors: Supporting neuronal survival
Mitochondrial stabilizers: Improving energy metabolism

Diagnostic Markers

Biomarkers for FUS Proteinopathy

CSF FUS levels: Elevated in some patients
Neurofilament light chain (NfL): Marker of neurodegeneration
Genetic testing: Confirmatory for mutation carriers
PET imaging: Experimental tracers for FUS pathology

Research Models

Cellular Models

Patient-derived iPSCs: Motor neurons from FUS mutation carriers
Mouse neurons: Primary cultures from transgenic models
Organoid systems: 3D brain organoids with FUS mutations

Animal Models

Transgenic mice: Express mutant human FUS
Knock-in models: Human mutations in endogenous mouse Fus
C. elegans: Simple model for screening
Zebrafish: Visual phenotypic screening

FUS Proteinopathy Neurons

FUS Proteinopathy Neurons

Introduction

FUS Proteinopathy Neurons

Introduction

Overview

FUS Biology

Normal Physiological Function

Pathological Changes in FUS Proteinopathy

Genetic Basis

Disease-Causing Mutations

Inheritance Patterns

Affected Brain Regions

Primary Affected Regions

Secondary Affected Regions

Pathogenic Mechanisms

RNA Processing Defects

Stress Granule Dysregulation

Nucleocytoplasmic Transport Defects

DNA Damage Sensitivity

Mitochondrial Dysfunction

Clinical Correlations

ALS Phenotype

FTD Phenotype

Therapeutic Approaches

Antisense Oligonucleotide (ASO) Therapy

Small Molecule Approaches

Gene Therapy

Neuroprotective Strategies

Diagnostic Markers

Biomarkers for FUS Proteinopathy

Research Models

Cellular Models

Animal Models

See Also